LifeStance Health Group (LFST) opened Q1 2026 with revenue of US$403.5 million and basic EPS of US$0.04, alongside trailing 12 month revenue of about US$1.5 billion and basic EPS of roughly US$0.06 as the company continues to build on its recent move into profitability. Over the last six reported quarters, revenue has stepped up from US$325.5 million in Q4 2024 to US$403.5 million in Q1 2026 while quarterly basic EPS has moved from a loss of US$0.02 to a profit of US$0.04. This sets a clear backdrop of improving earnings power that puts margins and their durability front and center for investors.

See our full analysis for LifeStance Health Group.

With the raw numbers on the table, the next step is to see how this earnings profile lines up with the widely followed growth and risk narratives around LifeStance and where those stories might need updating.

TTM profitability moves from loss to US$23.2 million

• On a trailing 12 month basis, net income swung from a loss of US$57.4 million in Q4 2024 to a profit of US$23.2 million in Q1 2026, with basic EPS moving from a loss of US$0.15 to a profit of about US$0.06 over the same window.
• Supporters of the bullish view point to this shift into profit and argue it can continue. However, the earnings path in the data is uneven, with quarterly net income ranging from a loss of US$7.1 million in Q4 2024 to a profit of US$14.2 million in Q1 2026. This means any thesis that assumes smooth improvement needs to account for how sensitive margins have been to small changes in revenue and costs.

Revenue growth around 13% meets rich valuation

• Trailing 12 month revenue sits at about US$1.5b, up from roughly US$1.3b a year earlier, which lines up with the 13.1% annual revenue growth figure that analysts are using in their rewards summary, while the stock trades on a trailing P/E of about 148x versus a healthcare industry average of 22.4x.
• Bulls highlight forecasts of around 60.5% yearly earnings growth and around 13.1% yearly revenue growth. Yet that optimism is tested by the gap between the current share price of US$8.85 and the DCF fair value of about US$0.76, as well as the P/E that is more than 6x the industry level, which leaves very little room in the numbers for slower growth or lumpier profitability.
• Consensus narrative notes that analysts as a group see earnings reaching US$111.7 million longer term, but the current trailing net income of US$23.2 million shows the company is still early in that earnings ramp.
• Critics highlight that even with 13.1% revenue growth, the combination of a 148x P/E and a DCF fair value well below the share price means valuation is very sensitive to whether the high growth forecasts actually show up in reported numbers.

LifeStance’s earnings shift and premium P/E are exactly what bullish investors focus on when they argue that today’s price reflects many years of growth already baked in, so it is worth seeing how that story is laid out in full before making a judgment. 🐂 LifeStance Health Group Bull Case

High growth forecasts versus cautious bears

• Bears lean on the current 148x P/E and the DCF fair value of US$0.76 to argue the stock is pricing in aggressive assumptions, while trailing 12 month earnings of US$23.2 million and EPS of about US$0.06 leave a fairly small profit base compared with the growth rates that are being mentioned.
• Skeptics warn that even the more cautious analyst cohort still relies on robust growth, with one bearish narrative using revenue assumptions of roughly mid teens annual growth and margin expansion from about 0.7% to 3.9%. The historical data showing quarterly net income flipping between small losses and modest profits suggests that if wage pressure, technology spending or reimbursement changes keep margins tight, the current multiple could be hard to justify on reported earnings alone.
• Bears also point out that the stock’s P/E sits well above the peer average of 56.4x and the sector at 22.4x, so any slowdown from the referenced 13.1% revenue growth rate could quickly make that multiple look stretched.
• At the same time, the company has not reported substantial insider selling in the last three months, which some investors see as reducing one typical bearish signal, even though it does not directly address concerns around valuation and competitive risk.

If you want to understand how cautious investors connect these valuation and competitive pressures to LifeStance’s latest results, it helps to see their thesis laid out side by side with the numbers. 🐻 LifeStance Health Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for LifeStance Health Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of optimism and concern around LifeStance is clear, so use the latest numbers, forecasts and narratives to stress test your own view. To see both sides of that story in one place, review the 2 key rewards and 1 important warning sign.

See What Else Is Out There

LifeStance’s 148x P/E, small profit base of US$23.2 million and uneven quarterly earnings leave little room for disappointment against optimistic growth assumptions.

If that mix of rich pricing and fragile earnings makes you cautious, it is worth checking companies screened as 51 high quality undervalued stocks to find ideas with more modest expectations baked in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.